These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31895414)

  • 1. Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome.
    Zhang A; Duchatelet S; Lakdawala N; Tower RL; Diamond C; Marathe K; Hill I; Richard G; Diab Y; Kirkorian AY; Watanabe F; Siegel DH; Hovnanian A
    JAMA Dermatol; 2020 Feb; 156(2):196-200. PubMed ID: 31895414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.
    Greco C; Leclerc-Mercier S; Chaumon S; Doz F; Hadj-Rabia S; Molina T; Boucheix C; Bodemer C
    JAMA Dermatol; 2020 Feb; 156(2):191-195. PubMed ID: 31895432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two for two: Dual therapy with erlotinib and acitretin for twins with severe keratoderma in Olmsted syndrome.
    Butala S; Phan S; Siegel DH; Carlberg V; Paller AS
    Pediatr Dermatol; 2023; 40(4):735-737. PubMed ID: 36709954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    Chiu CW; Nozawa H; Hanahan D
    J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
    Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M
    Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
    Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
    Schmid K; Bago-Horvath Z; Berger W; Haitel A; Cejka D; Werzowa J; Filipits M; Herberger B; Hayden H; Sieghart W
    Br J Cancer; 2010 Aug; 103(5):622-8. PubMed ID: 20683448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR Signaling Is Overactive in Pachyonychia Congenita: Effective Treatment with Oral Erlotinib.
    Basset J; Marchal L; Hovnanian A
    J Invest Dermatol; 2023 Feb; 143(2):294-304.e8. PubMed ID: 36116508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
    James R; Vishwakarma S; Chivukula IV; Basavaraj C; Melarkode R; Montero E; Nair P
    Cancer Med; 2012 Oct; 1(2):114-27. PubMed ID: 23342262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
    Birle DC; Hedley DW
    Mol Cancer Ther; 2006 Oct; 5(10):2494-502. PubMed ID: 17041093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
    Boehrer S; Galluzzi L; Lainey E; Bouteloup C; Tailler M; Harper F; Pierron G; Adès L; Thépot S; Sébert M; Gardin C; de Botton S; Fenaux P; Kroemer G
    Cell Cycle; 2011 Sep; 10(18):3168-75. PubMed ID: 21897118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
    Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
    Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
    Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
    Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonmutilating palmoplantar and periorificial kertoderma: a variant of Olmsted syndrome or a distinct entity?
    Nofal A; Assaf M; Nassar A; Nofal E; Shehab M; El-Kabany M
    Int J Dermatol; 2010 Jun; 49(6):658-65. PubMed ID: 20618471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
    Huang Z; Wu Y; Zhou X; Qian J; Zhu W; Shu Y; Liu P
    Future Oncol; 2015; 11(11):1687-99. PubMed ID: 26043220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.